

Clinical Updates in NON-SMALL CELL LUNG CANCER

New Management Strategies to Improve Patient Outcomes

Guidelines

NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (version 4), 2015
National Comprehensive Cancer Network, 20th Annual Edition. 2015.

▶ http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

NCCN Guidelines Patients: Non-Small Cell Lung Cancer (version 1), 2014

National Comprehensive Cancer Network, patient and caregiver resources.

▶ <http://www.nccn.org/patients/guidelines/nscl/index.html#10>

Other Resources

Lung Cancer Alliance

Founded in 1995, Lung Cancer Alliance is the oldest and leading nonprofit organization dedicated to saving lives and advancing research by empowering those living with and at risk for lung cancer.

▶ <http://www.lungcanceralliance.org/>

American Cancer Society

For over 100 years, the American Cancer Society has worked relentlessly to save lives and create a world with less cancer. Together with millions of our supporters worldwide, we help people stay well and get well, find cures, and fight back against cancer.

▶ <http://www.cancer.org/>

National Cancer Institute

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

▶ www.cancer.gov

Suggested Reading

Update on immune checkpoint inhibitors in lung cancer.

Creelan BC. *Cancer Control*. 2014;21(1):80-89.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/24357746>

Immune checkpoint inhibitors in clinical trials.

Sharon E, et al. *Chin J Cancer*. 2014;33(9):434-444.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/25189716>

Review of the current targeted therapies for non-small-cell lung cancer.

Nguyen KS, et al. *World J Clin Oncol*. 2014;5(4):576-587.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/25302162>

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, et al. *Nature*. 2014;515(7528):563-567.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/25428504>

A phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).

Antonia SJ, et al. *Ann Oncol*. 2014;25(suppl 4):iv426-iv470 abstr 1327P.

▶ <http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/NSCLC-Metastatic/A-Phase-I-open-label-study-to-evaluate-the-safety-and-tolerability-of-MEDI4736-an-anti-programmed-cell-death-ligand-1-PD-L1-antibody-in-combination-with-tremelimumab-in-patients-with-advanced-non-small-cell-lung-cancer-NSCLC>

Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An Update of ASCEND-1.

Felip E, et al. *Ann Oncol*. 2014;25(suppl 4):iv436-iv470 abstr 1295P.

▶ <http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/NSCLC-Metastatic/Efficacy-and-safety-of-ceritinib-in-patients-pts-with-advanced-anaplastic-lymphoma-kinase-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-An-update-of-ASCEND-1>

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, et al. *Lancet Oncol*. 2014;15(10):1119-1128.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/25153538>

Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer.

Soria J-C, et al. *Eur J Cancer*. 2014;50(suppl 6):199.

▶ [http://www.ejccancer.com/article/S0959-8049\(14\)70731-2/abstract](http://www.ejccancer.com/article/S0959-8049(14)70731-2/abstract)

Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC).

Yang JC, et al. *Ann Oncol*. 2014;25(suppl 4): iv149 abstr 449PD.

▶ http://annonc.oxfordjournals.org/content/25/suppl_4/iv149.2.abstract

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Seto T, et al. *Lancet Oncol*. 2014;15(11):1236-1244.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/25175099>

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Gainor JF, Shaw AT. *J Clin Oncol*. 2013;31(31):3987-3996.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/24101047>

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Brahmer JR, Pardoll DM. *Cancer Immunol Res*. 2013;1(2):85-91.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/24777499>

The blockade of immune checkpoints in cancer immunotherapy.

Pardoll DM. *Nat Rev Cancer*. 2012;12(4):252-264.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/22437870>

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Sequist LV, et al. *Ann Oncol*. 2011;22(12):2616-2624.

▶ <http://www.ncbi.nlm.nih.gov/pubmed/22071650>